Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariam Elmegaard

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
European Journal of Heart Failure|April 27, 2026
Modification of the association between age and mortality in heart failure by frailty statusCaroline Hartwell Garred, Mariam Elmegaard, Daniel Mølager Christensen, et al.
The Lancet Regional Health. Europe|February 11, 2022
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational studyAlexander C Falkentoft, Julie Andersen, Mariam Elmegaard Malik, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
Circulation. Cardiovascular Quality and Outcomes|October 9, 2025
Trends in Guideline-Directed Medical Therapies and Clinical Management in Patients With Prevalent Versus Incident Heart Failure: A Danish Nationwide Study From 1996 to 2022Emma Kidholm Boysen, Lars Køber, Mads Kristian Ersbøll, et al.
ESC Heart Failure|August 25, 2025
Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL-HFMariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, et al.
JACC. Heart Failure|June 11, 2026
A Randomized Clinical Implementation Trial Testing a Digital Strategy to Increase SGLT2 Inhibitor Initiation in Heart FailureMariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
European Journal of Heart Failure|April 27, 2026
Modification of the association between age and mortality in heart failure by frailty statusCaroline Hartwell Garred, Mariam Elmegaard, Daniel Mølager Christensen, et al.
The Lancet Regional Health. Europe|February 11, 2022
Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational studyAlexander C Falkentoft, Julie Andersen, Mariam Elmegaard Malik, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
Circulation. Cardiovascular Quality and Outcomes|October 9, 2025
Trends in Guideline-Directed Medical Therapies and Clinical Management in Patients With Prevalent Versus Incident Heart Failure: A Danish Nationwide Study From 1996 to 2022Emma Kidholm Boysen, Lars Køber, Mads Kristian Ersbøll, et al.
ESC Heart Failure|August 25, 2025
Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL-HFMariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, et al.
JACC. Heart Failure|June 11, 2026
A Randomized Clinical Implementation Trial Testing a Digital Strategy to Increase SGLT2 Inhibitor Initiation in Heart FailureMariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, et al.
Pageof 4